Biotech News and Comments
Good news: IPLEX™ will be used for ALS (Amyotrophic Lateral Sclerosis. IINSMED (INSM) is back on the drug. Bad news: Acorda received a refuse to file letter from the FDA, regarding its New Drug Application (NDA) for Fampridine-SR, developed to improve walking ability in people with multiple sclerosis (MS).
A Test for JC virus that causes PML in a tiny percentage of people on Tysabri is expected to become available at the end of this year.
25 Mar 2009
W do not find it smart of the critics to insinuate that publishing the results of Dendreon's study, which deals with survival, enables the firm and the physicians, let alone the patients, to change the outcome of the study.at the last minute. With regard to the suggestion that the patients are among the conspirators, the only possibility for them to conspire is that the dead among them would pretend they…
24 Mar 2009
With The evolution of sciences, We are expecting a consequent evolution in predictive medicine, including earlier detection of pathological organ injuries, as well as drug-related injuries. Such an evolution would contribute to safer, shorter and much less time, effort and cost of clinical trials and health care. Compugen has shown it is a front runner towards realizing this task.
OSI Pharmaceuticals (OSIP) and Genentech (DNA submitted a supplemental New Drug Application (sNDA) to the FDA for the use of Tarceva® (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer/.
12 Mar 2009
When you wake up and find out that Gilead (GILD) stock has lost over $1.40, don’t be afraid and do not think that the company has bad news. Investors’ reaction is nothing but a routine that happens when a firm declares it is acquiring another firm
10 Mar 2009
Ben Bernanke gave us the first flash of optimism about our future. Besides the economy, good news that came from Eurand (EURX) motivated us to write about this firm in the upcoming issue of Prohost Newsletter (for subscribers only),
03 Mar 2009
A sell-off of undervalued stocks that belongs to a solid firms with plenty of positive news is IRRATIONAL
What should we expect Amgen to do in case it likes the results of Cytokinetics' heart failure drug CK-1827452?
Prulifloxacin, a broad-spectrum fluoroquinolone antibiotic passes the safety and efficacy tests of the second of two double-blind pivotal Phase 3 trials. NDA will be filed.
